Daytime
Phoenix Life

Product Description

Phoenix Daytime is designed to help people get through their day. This cannabidiol (CBD) and terpene dominant product has been formulated with a focus on managing inflammation, anxiety and tension. For people seeking out an advanced CBD product, with high bio-availability, tasty peppermint flavor, this is a great starter.

Cannabinoid Extract Proprietor Compound

CANNABIDIOL (CBD), CANNABIGEROL (CBG),
>0.3% TETRAHYRDRACANNABINOL (THC)
AND OTHER TRACE CANNABINOIDS
A-HUMULENE , B-CARYOPHYLLENE , B-MYRCENE,
LINALOOL , P-CYMENE, A-PINENE, B-PINENE

Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

Global Distribution Strategy

Phoenix Daytime is defined under most cannabis laws with respect to sales and distribution, as an extract from Industrial Hemp. The use of these specific strains allow the product to be sold under am ever expanding global acceptance of CBD and its safety and low risk of addiction as cited by the World Health Organization. This allows for a greater level of distribution due the reduced levels of product control requirements.

Online

Due the product being classified as "CBD from Industrial Hemp", this product can be sold Online and exported to over 20 countries. To facilitate this, the product will be made available as Phoenix Daytime (LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.

Australia

Partner with local licensed producer for distribution under medical cannabis laws.

Europe

Online distribution under generic CBD classification.

Global Distribution

Now that 47 countries have legalized medical cannabis, the inter-country trade is starting to expand. Phoenix Life is focused on import and export of all of its products from company owned and partnered production facilities. Phoenix Daytime will initially be sold Online & in National Healthcare Management Agreements.

United States

Online distribution under hemp CBD classification. Equaliti License partnership.

Vanuatu

Product will be available as part of the Roll-out of the NHMA to commence 2021.

Medical History and Development Information

Initial and ongoing Studies with a range of ages of both male and female patients experienced a general sense of wellbeing, reduced inflammation and overall general wellness. This product is designed as a general CBD product, with specific terpene profiling. The product is designed to be sold in Soft Gel Capsules and Sub-lingual Sprays.

Clinical Stage

INITIAL CANDIDATE STRAIN / FORMULATION SELECTED
EFFICACY DATA COLLABORATED WITH RESEARCH TEAM
INITIAL PATIENT GROUP SUCCESS
LARGER PATIENT GROUP SUCCESS
FORMALIZED CLINICAL TRIALS
APPROVED FOR SALE IN LOCAL MARKET
EXEMPTION AVAILABLE FOR IMMEDIATE SALES

LEGEND ☐ Completed ☐ Next Step ☐ Not Completed

Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at https://pubmed.ncbi.nlm.nih.gov/28232276/
2017 Jul;175:133-150. DOI: 10.1016/j.pharmthera.2017.02.041 PMID: 22155112 Am J Pathol. 2012 Feb; 180(2): 432–442.

Cannabidiol: State of the art and new challenges for therapeutic applications

Authors: Simona Pisanti , Anna Maria Malfitano , Elena Ciaglia, Anna Lamberti, Roberta Ranieri, Gaia Cuomo , Mario Abate , Giorgio Faggiana , Maria Chiara Proto , Donatella Fiore , Chiara Laezza

Abstract:Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids. Δ9-THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both compounds have been suggested. However, CBD is recently emerging as a therapeutic agent in numerous pathological conditions since devoid of the psychoactive side effects exhibited instead by Δ9-THC. In this review, we highlight the pharmacological activities of CBD, its cannabinoid receptor-dependent and -independent action, its biological effects focusing on immunomodulation, angiogenetic properties, and modulation of neuronal and cardiovascular function. Furthermore, the therapeutic potential of cannabidiol is also highlighted, in particular in nuerological diseases and cancer.

Phoenix Life Sciences Pty Ltd
Level 16, No1 Martin Place Sydney Australia

www.phoenixlife.co